Expertise in
8
conditions

Pierre Desreumaux

Lille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Lille, FR 
OverviewLocationsClinical Research

Overview

Pierre Desreumaux practices in Lille, France. Mr. Desreumaux is highly rated in 8 conditions, according to our data. His top areas of expertise are Crohn's Disease, Viral Gastroenteritis, Colitis, Lactose Intolerance, and Endoscopy.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Lille, France
Other Locations
Nancy, France
Marcq, 59700, France
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Evaluation of the Expression of Natural Killer T Cells (NKT) Marker in the Gut of Patients With Primary Sclerosing Cholangitis (PSC) Complicated by an Inflammatory Bowel Disease (IBD)
Evaluation of the Expression of Natural Killer T Cells (NKT) Marker in the Gut of Patients With Primary Sclerosing Cholangitis (PSC) Complicated by an Inflammatory Bowel Disease (IBD)
Enrollment Status: Completed
Publish Date: August 27, 2020
Intervention Type: Other
Study Phase: Not Applicable
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
Enrollment Status: Terminated
Publish Date: February 15, 2019
Intervention Type: Other
Modulation of Lactase Expression by a New Synthetic PPARgamma Ligand in Ex-vivo Cultures of Duodenal Biopsies
Modulation of Lactase Expression by a New Synthetic PPARgamma Ligand in Ex-vivo Cultures of Duodenal Biopsies
Enrollment Status: Completed
Publish Date: October 17, 2018
Intervention Type: Drug
Study Phase: Not Applicable
Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial
Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial
Enrollment Status: Completed
Publish Date: June 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

97 Total Publications

Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study.
Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study.
Journal: Therapeutic advances in gastroenterology
Published: October 05, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Desreumaux's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile